Search PubMedSearch

PubMed · 8101646

[New strategy for thyroid function testing].

Abstract

The authors used a new protocol, based upon a supersensitive TSH assay, to examine the thyroid status of 1720 patients. Based upon the serum hormone levels, the patients were divided into different clinical groups. The biochemical relationship between the different hormone levels, and the rate of occurrence of various thyroid diseases were studied. 76.1% of the new patients hadn't received any previous treatment. 15.5% of those patients who had received treatment had hyperthyroidism, while 8.4% of those had hypothyroidism. 76% of the new patients, 38.3% of those who had hyperthyroidism, and only 29.7% of those who had hypothyroidism, were euthyroid. Undetectable TSH levels (< 0.03 mU/L) where observed in 51.8% of the new hyperthyroid patients, and in 33.8% of those who had subclinical hyperthyroidism. Similar results were obtained with those who had been previously treated for hyperthyroidism. The new protocol has the following advantages: it's more convenient to the patients, it's quick, it's economical. With this method it is possible to reduce the assays per patient by 31%. The algorithm was supplemented with results of free hormone levels. By doing this the authors were able to measure free-T4 and T3 hormone levels of 150 more patients. According to the authors, the free-T4 test is more informative than the free-T4-index, especially in the border-line cases and in treated hyperthyroidism. Primarily the free-T3 test is most necessary when examining patients treated with methimasol.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Toldy, Z Löcsei, S Héber, K Gundy, L Varga, L G Kovács. 1993-07-18. [New strategy for thyroid function testing].. https://pubmed.ncbi.nlm.nih.gov/8101646/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction.

OBJECTIVE: Our purpose was to measure cardiologists' level of adherence to guidelines for long-term use of beta-adrenergic blocker therapy after acute myocardial infarction. BACKGROUND: Beta-blocker therapy after acute myocardial infarction has been shown to reduce the incidence of reinfarction and associated mortality. To learn about cardiologists' use of this therapy after hospital discharge and their level of adherence to American College of Cardiology guidelines, we analyzed insurance claims from 17 network-model health plans located throughout the United States. METHODS: The study group included 150 cardiologists who had contracts with one of the health plans and their 280 patients who were plan members (excluding Medicare enrollees) and received inpatient treatment for acute myocardial infarction that did not include revascularization during 1992. These patients accounted for 307 separate hospital admissions. Insurance claims were used to measure beta-blocker usage and to identify possible contraindications. RESULTS: Forty-three percent of the cases (131 of 307) involved apparent deviations from the guidelines: 11% of cases (35 of 307) involved possible errors of commission (beta-blocker given in the presence of a contraindication) and 31% (96 of 307) errors of omission (beta-blocker not given in the absence of a contraindication). Of the 185 patients who were eligible for the therapy (no contraindications), only 48% (89 of 185) were treated. CONCLUSIONS: Cardiologists currently exhibit a low level of compliance with their specialty's guidelines for postinfarction beta-blockade. Slightly fewer than 50% of the study patients who were eligible for treatment actually received a beta-blocker after hospital discharge. This result, combined with the drug's known level of effectiveness in preventing recurrent myocardial infarction, suggests that increased use could avert approximately 1,900 deaths annually nationwide.

Adrenergic beta-Antagonists